September 20, 2022

Junshi Biosciences Receives NMPA Approval of sNDA for Toripalimab in Combination with Chemotherapy as First-Line Treatment for Advanced Non-squamous Non-Small Cell Lung Cancer

–6th approved indication of toripalimab in China, bringing more treatment options to patients with advanced NSCLC SHANGHAI, China, Sept. 20, 2022 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company

Read More

Nasdaq Establishes New Digital Assets Business

Underpins Nasdaq’s Focus on Advancing the Transformation of Markets and Driving Broader Institutional Adoption of Digital Assets Subject to Regulatory Approval, Nasdaq Digital Assets Will Provide a Proprietary Custody Solution with Liquidity and Execution Services for Financial Institutions Appoints Ira

Read More
Recent Post
Pages
Recent Post